Breast

King Charles is having cancer treatment. What can he, and others with cancer, expect?

Retrieved on: 
Wednesday, February 7, 2024

The type of cancer has not been revealed, but it has been confirmed it is not prostate cancer.

Key Points: 
  • The type of cancer has not been revealed, but it has been confirmed it is not prostate cancer.
  • So what can King Charles and the millions of others who are newly diagnosed with cancer each year expect?

What actually is cancer?

  • Normally, cells multiply and die in a regulated way, so each new cell replaces a cell that is lost.
  • The cancer cells can break away and travel through the bloodstream or lymph vessels to other parts of the body.
  • If the primary cancer cells grow and form another tumour at a new site, it is called a secondary cancer or metastasis.


Read more:
How does cancer spread to other parts of the body?

Millions of new cases each year

  • And King Charles’ diagnosis is one of roughly 19.3 million new cases of cancer diagnosed worldwide each year.
  • The most common cancers can vary between countries, due to a number of factors such as genetics, lifestyle and environment.
  • In Australia, for example, the most common cancers are prostate, breast, skin melanoma, colorectal cancer and lung cancer.

Cancer accounts for 1 in 6 deaths

  • Worldwide, leading cancer-related deaths are from lung, colorectal, stomach, breast, pancreatic, oesophageal, prostate and liver cancer.
  • In 2023, there were roughly 165,000 cases of cancer diagnosed and 51,000 cancer deaths in Australia.

But more people are surviving cancer

  • Advances in medicine and treatments for cancer have led to more people surviving cancer.
  • This therapy destroys cancer cells using a controlled dose of radiation to kill or damage cancer cells so they cannot grow, multiply or spread, while sparing surrounding healthy tissue.
  • There is also “CAR T-cell therapy”, which harnesses the body’s own immune system to fight against cancer.
  • Thanks to COVID, mRNA technology and other nanoparticle delivery systems are also an area yielding promising results for cancer vaccines.

Do treatments work?

  • With such new treatments, cancer survival rates have improved significantly.
  • In Australia, for example, five-year survival rates improved from 52% to 70% from 1989–1993 to 2014–2018.

In a nutshell


King Charles’ cancer diagnosis, at the age of 75, is one of millions of new cancer diagnoses globally. While cancer remains a leading cause of death worldwide, survival rates are improving thanks to extensive advances in treatments and treatment options.

Read more:
What happens if King Charles can no longer perform his duties?


Sathana Dushyanthen does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 6, 2024

In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.

Key Points: 
  • In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter and year ended December 31, 2023, Exelixis earned $40.7 million and $148.5 million, respectively, in royalty revenues.
  • In October 2023, detailed results were presented from the phase 3 CABINET pivotal trial at the 2023 ESMO Congress.
  • Exelixis management will discuss the company’s financial results for the fourth quarter and fiscal year of 2023 and provide a general business update during a conference call beginning at 5:00 p.m.

OneOncology and Coastal Cancer Center Purchase Two Radiation Oncology Centers and Partner with Three South Carolina Radiation Oncologists in Myrtle Beach and Conway

Retrieved on: 
Tuesday, February 6, 2024

NASHVILLE, Tenn. and MYRTLE BEACH, S.C., Feb. 6, 2024 /PRNewswire/ -- OneOncology, the fastest-growing national platform for independent oncology practices, and its South Carolina-based partner, Coastal Cancer Center, announced they have purchased two radiation oncology centers located in Myrtle Beach and Conway, South Carolina from GenesisCare. As part of the transaction, three radiation oncologists and 40 employees will join Coastal Cancer Center and continue caring for patients at both locations.  

Key Points: 
  • NASHVILLE, Tenn. and MYRTLE BEACH, S.C., Feb. 6, 2024 /PRNewswire/ -- OneOncology, the fastest-growing national platform for independent oncology practices, and its South Carolina-based partner, Coastal Cancer Center, announced they have purchased two radiation oncology centers located in Myrtle Beach and Conway, South Carolina from GenesisCare.
  • As part of the transaction, three radiation oncologists and 40 employees will join Coastal Cancer Center and continue caring for patients at both locations.
  • OneOncology and Coastal Cancer Center are purchasing two radiation oncology centers located in Myrtle Beach and Conway.
  • The Myrtle Beach radiation oncology center is located at 4708 Oleander Drive and the Conway center is at 8059 Myrtle Trace Drive.

Is your pet exposed to secondhand smoke? Here are the (serious) health risks

Retrieved on: 
Tuesday, February 6, 2024

Between 80 and 90% of lung cancer cases are associated with exposure to cancer-causing componds from first-or second-hand smoking.

Key Points: 
  • Between 80 and 90% of lung cancer cases are associated with exposure to cancer-causing componds from first-or second-hand smoking.
  • Children’s oral health, development, and future health outcomes are also negatively affected by exposure to secondhand smoke.
  • Exposure to secondhand smoke is a common but avoidable risk factor for health concerns in pets and people alike.
  • Reducing exposure to secondhand smoke, can enhance overall health, welfare and longevity for both pets and their people.

Employers Agree Relying on Primary Care and Insurance Coverage Is Not Enough To Meet Cancer Screening Needs, According to New Survey

Retrieved on: 
Tuesday, February 6, 2024

BURLINGAME, Calif., Feb. 6, 2024 /PRNewswire/ -- Color Health today announced findings from its recent survey, conducted by The Harris Poll, highlighting employer perspectives on the rising cost of cancer, priorities for providing the most impactful care to employees, and potential strategies for reducing the burden of cancer on the workforce. Details are available in Color Health's 2024 Employer Insights Report: The State of Cancer.

Key Points: 
  • In 2024, over two-thirds (62%) of employers plan to offer a cancer screening program as a strategy for early detection and reducing costs.
  • Additional key findings include:
    Screening, early detection, and risk assessment/prevention are the highest priorities for cancer benefits, according to over 70% of benefits leaders.
  • 72% of benefits leaders agree that primary care providers are not getting enough employees screened for cancer.
  • "Because they provide healthcare coverage for nearly half of all Americans, employers are uniquely positioned to address gaps in cancer care.

Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities

Retrieved on: 
Monday, February 5, 2024

The American Cancer Society (ACS) and Pfizer Inc. (NYE: PFE) today announced the launch of “Change the Odds™: Uniting to Improve Cancer Outcomes,” a three-year initiative to bridge the gap in cancer care disparities.

Key Points: 
  • The American Cancer Society (ACS) and Pfizer Inc. (NYE: PFE) today announced the launch of “Change the Odds™: Uniting to Improve Cancer Outcomes,” a three-year initiative to bridge the gap in cancer care disparities.
  • “Change the Odds” will initially focus on breast and prostate cancer in medically underserved communities, with the potential to expand to additional cancer types.
  • “Cancer doesn’t discriminate – and neither should cancer care,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.
  • “Everyone should have the same opportunity to access the latest advances in care, regardless of their background or where they live.

PRISM MarketView Marks World Cancer Day

Retrieved on: 
Thursday, February 1, 2024

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.

Key Points: 
  • NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.
  • To mark World Cancer Day , which will be held on February 4, PRISM MarketView highlights emerging companies working to improve the lives of cancer patients and their families by developing and commercializing innovative new treatments for cancer.
  • The company has entered a research agreement with the Johns Hopkins University School of Medicine for the development of Ivospemin.
  • Essa Pharma, a clinical stage pharmaceutical company, is focused on the development of small molecule drugs for the treatment of prostate cancer.

New investigator-initiated clinical trials of BellaSeno´s resorbable tissue regeneration scaffolds to be conducted in Europe

Retrieved on: 
Wednesday, January 31, 2024

In 2023, BellaSeno had received market authorization for its custom-made, resorbable bone and pectus excavatum scaffolds in Europe.

Key Points: 
  • In 2023, BellaSeno had received market authorization for its custom-made, resorbable bone and pectus excavatum scaffolds in Europe.
  • The clinical pectus excavatum trial in Italy will enroll a total of 10 patients, with 4 individuals having undergone surgery already.
  • While initial clinical use cases in Australia demonstrated promisingoutcomes last year, this is the first time that a fully resorbable sternal prosthesis is being used in Europe.
  • "We are excited that several leading European university hospitals have decided to evaluate our scaffolds in independent clinical trials.

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Retrieved on: 
Tuesday, January 30, 2024

During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.
  • OGM is helping to unravel persistent, complex mysteries in genetic disease that impact people, even in more common disorders like Down syndrome and Marfan syndrome.
  • OGM has the potential to meet the key requirements of the cell and gene therapy community.
  • “I would encourage anyone who was unable to attend live to login, view these presentations and see how bright the future of cytogenetics is with OGM.”

Global Breast Implants Pipeline Research Report 2023: Development Stages, Segments, and Key Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 30, 2024

The "Breast Implants Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Breast Implants Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering.
  • The medical devices industry witnesses the publication of an in-depth analysis spotlighting the progressive landscape of breast implants.
  • This detailed 2023 pipeline report provides diligent insights into products at various development phases, alongside illuminative data on ongoing clinical trials within the sector.
  • Spanning sizers, expanders to a range of gel and saline implants, the coverage in this report encompasses a broad spectrum of breast implant technologies.